Skip to main content
OpenTrials
Completed

NCT Number: NCT06087991

Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment

This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.

Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Utah

Salt Lake City, Utah, 84108, United States

About this study

Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.

The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.

This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For qualitative interviews with providers, administrators, stakeholders:

  • Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder.

For the quantitative surveys:

  • Must be a Castleview Hospital patient who receives the BINDeR-Tx model.

Exclusion criteria

For qualitative interviews with providers, administrators, stakeholders:

  • Not familiar with the BINDeR-Tx model
  • No interaction with the BINDeR-Tx model

For the quantitative surveys:

  • Unable to speak and read English
  • Subject is unable to provide contact information

Treatment and study plan

Implementation of the BINDeR-Tx service model

Behavioral

ED-initiated buprenorphine, discharge with naloxone, and warm-hand off referral for continued treatment for individuals with OUD. This is considered standard treatment at the University of Utah ED. In order to extend these services to rural hospitals this study will be assisting Castleview Hospital to establish a similar program.

Primary outcomes

  1. Patient Focused: Number of patients receiving services.

    Time frame: 24 months

    Will be the aggregate number of individuals who received ED-initiated buprenorphine.

Secondary outcomes

  1. Implementation and service quality: Satisfaction with projected service

    Time frame: 24 months.

    Qualitative interviews including clinicians, hospital staff, and community members associated with Castleview Hospital will be the investigators using the Consolidated Framework for Implementation Research (CFIR).

  2. Implementation and service quality: Patient satisfaction

    Time frame: enrollment and 6 months post enrollment

    Patient satisfaction will be assessed using the Patient Satisfaction Questionnaire Short Form (PSQ-18)

  3. Substance use diagnosis and treatment

    Time frame: enrollment and 6 months post enrollment

    Using the Government Performance and Results Act (GPRA) Outcome questions on substance use within the past 30 days, other substance use disorder diagnoses and treatment in the past 30 days, and mental health diagnoses.

  4. Social Connectedness

    Time frame: enrollment and 6 months post enrollment

    Social connectedness will be measured using the GPRA questions on mutual support group attendance in the last 30 days and relationship satisfaction and support.

  5. Living Conditions

    Time frame: enrollment and 6 months post enrollment

    Living conditions will be measured using the GPRA questions on residence within the past 30 days.

  6. Mental and Physical Health Problems and Treatment/Recovery

    Time frame: enrollment and 6 months post enrollment

    Mental and physical health problems and treatment/recovery will be measured using the GPRA questions on mental health symptoms and medical care received in the past 30 days and insurance status.

  7. Legal Status

    Time frame: enrollment and 6 months post enrollment

    Legal status will be measured using the GPRA questions on incarceration in the past 30 days, charges, trial, sentencing, parole, probation, and drug court status.

  8. Discharge status

    Time frame: enrollment and 6 months post enrollment

    Discharge status will be measured using the GRPA questions on substance use diagnosis and treatment in the past 30 days.

  9. Follow-up Status

    Time frame: enrollment and 6 months post enrollment

    Follow-up status will be measured using the GPRA questions on contact and follow-up status.

  10. Education, Employment, and Income

    Time frame: enrollment and 6 months post enrollment

    Education, employment, and income will be measured using the GPRA questions on education level, employment status, living expenses and income status.

Sponsors and collaborators

Lead sponsor

Jerry Cochran

Other

Registry information

Acronym: BINDeR-TX

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 18, 2023
Registry last updated
Jun 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.